Pregnancies for patients on dialysis are high risk and care by a multidisciplinary team is extremely important for a successful birth, explained Silvi Shah, MD, MS, FASN, assistant professor, Division of Nephrology and Hypertension, University of Cincinnati.
Patients on dialysis who are pregnant should be treated by a nephrologist, a maternal-fetal specialist, and a neonatologist due to the high-risk nature of the pregnancy, said Silvi Shah, MD, MS, FASN, assistant professor, Division of Nephrology and Hypertension, University of Cincinnati.
Transcript
What are some of the steps that can be taken to treat and monitor pregnant individuals on dialysis and improve the odds of a successful pregnancy?
One of the things is care by a multidisciplinary team is extremely, extremely important. They should be followed by a nephrologist or a kidney doctor. They should have maternal-fetal medicine, which is a high-risk obstetrician, and at the same time, they will likely need neonatology care, as well, because most of the babies who are born are low birth weights and are preterm. So, we really stress all these pregnancies to be monitored in a tertiary care center, which has a level 3 NICU [neonatal intensive care unit] there. So multidisciplinary care is extremely, extremely important to have successful outcomes.
Following delivery, how should treatment be adjusted and are there any postpartum complications that patients should be monitored for?
I think treatment after delivery, we just have to monitor both the mother and the baby very closely. Breastfeeding is safe, postpartum, if they are not on any medications, which can be teratogenic. It is usually encouraged in these women. We also have to make sure their blood pressure is under good control. If they had any history of preeclampsia or hypertension during pregnancy, we will have to monitor their blood pressure to make sure that is under good control.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More